LABA/LAMA vs placebo
COPD exacerbations · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler probably leads to lower acute exacerbations of COPD (4‐week to 24‐week compared with placebo (moderate certainty).
1 finding from 1 review
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes onlyOR 0.53 [0.36, 0.78]3 studies · 1127 participantsModerate